Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

Author： Rothmann Mark   Koti Kallappa   Lee Kyung Yul   Lu Hong Laura   Shen Yuan Li   Zhang Jenny J.   Jin Mei   Zhou Haojin  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.23, Iss.5, 2013-09, pp. : 1091-1105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical Trials

By Denne J. S.   Stone A. M.   Bailey-Iacona R.   Chen T.-T.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 951-970

Taylor & Francis Ltd

Access to resources Recommend Favorite

HIV-1 immunogen does not appear to improve HIV progression-free survival

By  

Inpharma, Vol. 1, Iss. 1263, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

By Lipton Allan  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 749-762

Informa Healthcare

Access to resources Recommend Favorite

Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

By Matulonis Ursula A.   Oza Amit M.   Ho Tony W.   Ledermann Jonathan A.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

Blackwell Publishing

Access to resources Recommend Favorite

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas   Eichelberg Christian   Sun Maxine  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite